Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes
about
Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acidsNSAIDs Ibuprofen, Indometacin, and Diclofenac do not interact with Farnesoid X Receptor.Pharmacophore-based discovery of FXR agonists. Part I: Model development and experimental validation.Conformational dynamics of human FXR-LBD ligand interactions studied by hydrogen/deuterium exchange mass spectrometry: insights into the antagonism of the hypolipidemic agent Z-guggulsterone.Pharmacophore-based discovery of FXR-agonists. Part II: identification of bioactive triterpenes from Ganoderma lucidumQuantitative high-throughput profiling of environmental chemicals and drugs that modulate farnesoid X receptorChemistry and biology of multicomponent reactions.Medicinal chemistry of farnesoid X receptor ligands: from agonists and antagonists to modulators.Characterizing ligands for farnesoid X receptor--available in vitro test systems for farnesoid X receptor modulator development.Farnesoid X receptor modulators (2011 - 2014): a patent review.Blinded evaluation of farnesoid X receptor (FXR) ligands binding using molecular docking and free energy calculations.Combining self- and cross-docking as benchmark tools: the performance of DockBench in the D3R Grand Challenge 2.Differential regulation of bile acid and cholesterol metabolism by the farnesoid X receptor in Ldlr -/- mice versus hamsters.D3R Grand Challenge 2: blind prediction of protein-ligand poses, affinity rankings, and relative binding free energies.Simultaneous diastereo- and enantioseparation of farnesoid X receptor (FXR) agonists with a quinine carbamate-based chiral stationary phase.eTOX ALLIES: an automated pipeLine for linear interaction energy-based simulations.Impact of domain knowledge on blinded predictions of binding energies by alchemical free energy calculations.Lessons learned in induced fit docking and metadynamics in the Drug Design Data Resource Grand Challenge 2.Using physics-based pose predictions and free energy perturbation calculations to predict binding poses and relative binding affinities for FXR ligands in the D3R Grand Challenge 2.Workflows and performances in the ranking prediction of 2016 D3R Grand Challenge 2: lessons learned from a collaborative effort.CDOCKER and λ-dynamics for prospective prediction in D₃R Grand Challenge 2.Binding free energy predictions of farnesoid X receptor (FXR) agonists using a linear interaction energy (LIE) approach with reliability estimation: application to the D3R Grand Challenge 2.
P2860
Q24628720-519D4B40-D1FE-420D-A33A-07A5D001F551Q30666362-6D4E4B96-4138-413F-82C6-EC4555894B99Q34054283-62A2871C-8C93-4EF1-8535-346FEB034174Q34065876-83AB7B84-9214-4BE8-BB78-9A2B8D1744C4Q35662134-B45AE3B7-2721-4C0E-94B8-75C9A7F4F615Q36972583-9207D6B6-27C6-4A17-B354-4B277BE00D99Q37017587-F31A5D9B-C3A5-412B-B483-A84E95D489AFQ38014901-FC93D1E1-B270-4FF1-823E-94921D03FCD7Q38164798-B1912537-E2C0-4E1C-82F8-982364E85A3AQ38548688-AAADF8C1-820C-46D6-B92C-5AF472F06090Q38597033-4507D856-19FB-4049-B251-DD8D01EFB42FQ38608749-BE73B487-E9F3-4689-8BA8-5572E0CED86CQ39741716-F7195033-FAA8-48A0-8BCC-E02659EDD7F2Q46050747-D4ADF1C9-2199-4CDB-B557-F754DED4F572Q46739028-6F587F18-9761-4E25-8E07-689D11E7A613Q47166149-CACFA2AC-7C01-475E-8C6A-25625304416BQ47406205-F93408F1-EAA2-4D60-9BDA-A20E7BEF02F4Q47414331-0B14DAEC-567C-46E9-82F5-C616B2B5033BQ47614697-49D50DB7-208A-4BBD-AE99-7FD677FE3498Q47684449-3DE2570E-5F57-4E36-B41C-ADEE50161F82Q47694932-17F21C33-17FF-4109-AE06-1F31FC76E3A9Q47827032-C003C010-7927-4A49-9033-9AFC40F23952
P2860
Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes
description
2011 nî lūn-bûn
@nan
2011 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@ast
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@en
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@nl
type
label
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@ast
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@en
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@nl
prefLabel
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@ast
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@en
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@nl
P2093
P1476
Discovery of novel and orally ...... ent of dyslipidemia & diabetes
@en
P2093
Bernd Kuhn
Christophe Gardes
Denise Blum
Evelyne Chaput
Franz Schuler
Gregory M Benson
Hans G F Richter
Jean-Marc Plancher
Konrad H Bleicher
Markus G Rudolph
P356
10.1016/J.BMCL.2010.11.039
P407
P577
2011-01-01T00:00:00Z